Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Over 50 Patients Enrolled Thus Far in Phase 2b Trial of Halneuron® in ...

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

The trial aims to assess the regimen over a 90-day period for those with a presumptive diagnosis of the condition.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Historically, more than half of patients with GM2 gangliosidosis need to be fed via IV between 13 and 18 months of age. In ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...